Agents such as metformin, statins, COX-2 inhibitors, and hydroxychloroquine target distinct nodes in this network, from lowering IL-6 and PD-L1 to reprogramming myeloid populations and constraining tumor survival pathways. This evidence concerns the gene CD274 and neoplasm.